Sangamo Therapeutics, Inc.

( )
SGMO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 16.35%127.030.0%$2227.08m
BIIBBiogen, Inc. 0.84%243.781.7%$657.15m
AMGNAmgen, Inc. 2.04%224.811.3%$567.96m
GILDGilead Sciences, Inc. 0.89%60.031.0%$514.37m
NVAXNovavax, Inc. 22.51%125.6992.9%$508.55m
BNTXBioNTech SE 4.79%109.990.0%$483.37m
VRTXVertex Pharmaceuticals, Inc. 3.95%226.711.9%$475.11m
REGNRegeneron Pharmaceuticals, Inc. 1.13%514.052.7%$473.60m
ILMNIllumina, Inc. 4.29%317.033.5%$393.59m
APVOAptevo Therapeutics, Inc. 1.32%44.3918.3%$233.60m
SGENSeagen Inc. 2.22%169.125.8%$182.62m
EXASEXACT Sciences Corp. 2.00%118.1919.6%$179.47m
ALXNAlexion Pharmaceuticals, Inc. 0.73%123.832.0%$157.60m
HALOHalozyme Therapeutics, Inc. -2.21%40.2318.4%$131.67m
SRNESorrento Therapeutics, Inc. 18.12%8.151.4%$127.58m

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.